Exciva GmbH’s EUR 9 Million Series A Funding Round

Bird & Bird has advised Exciva GmbH on the deal.

Exciva GmbH, a clinical biotech company which is developing a novel therapy for the treatment of agitation and aggression in Alzheimer’s disease, raised capital through its Series A financing led by Andera Partners. LBBW Venture Capital and Cure8 also participated in the financing round.

The initial funding will be used by Exciva to develop its lead product to Phase I completion. The compound is a combination of two clinically approved products that have a proven efficacy in treating the central nervous system.

Exciva GmbH was advised by the following Bird & Bird lawyers: Associate Marcel Nurk, partner Stefan Münch (Picture) and counsel Michael Gaßner, all corporate law/M&A, Munich.

Involved fees earner: Michael Gaßner – Bird & Bird; Stefan Münch – Bird & Bird; Marcel Nurk – Bird & Bird;

Law Firms: Bird & Bird;

Clients: Exciva GmbH;

Giulia Di Palma

Author: Giulia Di Palma